Pipecuronium
Arduan (pipecuronium) is a small molecule pharmaceutical. Pipecuronium was first approved as Arduan on 1990-06-26.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Pipecuronium bromide
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
ARDUAN | Organon | N-019638 DISCN | 1990-06-26 | 1 products |
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
38 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Parkinson disease | D010300 | EFO_0002508 | G20 | — | 6 | 4 | 4 | 1 | 15 |
Sleep initiation and maintenance disorders | D007319 | F51.01 | — | 1 | — | 2 | — | 3 | |
Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | — | 1 | — | 2 | — | 3 |
Neurodegenerative diseases | D019636 | EFO_0005772 | G31.9 | — | — | 2 | 1 | — | 3 |
Dementia | D003704 | F03 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Schizophrenia | D012559 | EFO_0000692 | F20 | — | 3 | 3 | — | — | 6 |
Psychotic disorders | D011618 | F20.81 | — | 2 | 1 | — | — | 3 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Alzheimer disease | D000544 | EFO_0000249 | F03 | — | 3 | — | — | — | 3 |
Dyskinesias | D020820 | G24 | — | 1 | — | — | — | 1 | |
Hallucinations | D006212 | HP_0000738 | F06.0 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Tourette syndrome | D005879 | EFO_0004895 | F95.2 | 1 | — | — | — | — | 1 |
Tardive dyskinesia | D000071057 | G24.01 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | PIPECURONIUM |
INN | pipecuronium bromide |
Description | Pipecuronium bromide is a steroid ester. |
Classification | Small molecule |
Drug class | quaternary ammonium derivatives: neuromuscular blocking agents; quaternary ammonium derivatives: neuromuscular blocking agents |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@H](CC[C@@]4(C)[C@H]3C[C@H](N3CC[N+](C)(C)CC3)[C@@H]4OC(C)=O)[C@@]2(C)C[C@@H]1N1CC[N+](C)(C)CC1 |
Identifiers
PDB | — |
CAS-ID | 52212-02-9 |
RxCUI | 66983 |
ChEMBL ID | CHEMBL1201206 |
ChEBI ID | 8230 |
PubChem CID | 65332 |
DrugBank | — |
UNII ID | R6ZTY81RE1 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 185 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
21,809 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more